In this issue:
Anti-JCV antibody indices with ocrelizumab
EBNA-1 peptide antibodies in MS vs. MOGAD/NMOSD
SMART-MS: intrathecal autologous mesenchymal stem cell therapy in progressive MS
Real-world natalizumab vs. ocrelizumab/rituximab
MS disease trajectory in menopause
Genetic markers of MS susceptibility in African/South Asian ancestry
Exposure to industrial dust & risk of MS
Real-world performance of 2024 McDonald criteria
Relapse recovery for up to 1 year in RRMS
KFLC as a marker of treatment response/progression
Please login below to download this issue (PDF)